Other
Rezolute
Total Trials
5
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed trials have results
Key Signals
1 recruiting1 with results
Enrollment Performance
Analytics
Phase 2
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 2(2)
Phase 3(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT06881992Phase 3Recruiting
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Role: lead
NCT06208215Phase 3Active Not Recruiting
RZ358 Treatment for Congenital Hyperinsulinism
Role: lead
NCT07262970Unknown
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Role: lead
NCT05712720Phase 2Completed
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
Role: lead
NCT04538989Phase 2Completed
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
Role: lead
All 5 trials loaded